Announced Sat, 16 May · 14:45 IST

Annual Secretarial Compliance Report for the FY 2025-26

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹516.90
prior close
₹512.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+2.6+3.8+1.2+0.6-0.9+1.3+0.8+0.8+3.7+5.3+16.6+30.9
Up moveDown movePending
AI summary

Akums Drugs and Pharmaceuticals Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended 31 March 2026, as mandated under SEBI Regulation 24A. The report was issued by M/s. SPG & Associates, Practicing Company Secretaries. The secretarial auditor confirms that the company has generally complied with applicable SEBI regulations including LODR 2015, PIT Regulations, SBEB Regulations, and Depositories Regulations. However, the report flags that the National Stock Exchange of India imposed a fine of Rs. 5.95 lakh on the company for non-compliance with Regulation 17(1)(b) of the Listing Regulations, which relates to board composition requirements. No additional non-compliances were observed, and there were no resignations of statutory auditors during the review period.

Likely market impact

The NSE fine of Rs. 5.95 lakh for board composition non-compliance under Regulation 17(1)(b) is a minor governance concern. Shareholders should monitor whether the company has addressed this compliance gap and ensured proper board composition going forward.